Sanofi (SNY) Cash & Equivalents (2009 - 2026)

Sanofi has disclosed Cash & Equivalents across 18 years of filings, most recently posting $6.9 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $6.9 billion, down 24.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 billion (down 24.87% YoY), and the FY2025 annual result was $8.9 billion, up 12.09% from the prior year.
• Cash & Equivalents came in at $6.9 billion for Q1 2026 at Sanofi, down from $8.9 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.9 billion in Q2 2023 to a low of $6.9 billion in Q1 2023.
• The 5-year median for Cash & Equivalents is $9.1 billion (2025), against an average of $9.4 billion.
• Peak annual rise in Cash & Equivalents reached 28.71% in 2023, while the deepest fall reached 38.34% in 2023.
• Sanofi's Cash & Equivalents stood at $13.0 billion in 2022, then retreated by 27.88% to $9.4 billion in 2023, then slipped by 15.15% to $8.0 billion in 2024, then grew by 12.09% to $8.9 billion in 2025, then retreated by 22.23% to $6.9 billion in 2026.
• The last three Cash & Equivalents figures came in at $6.9 billion (Q1 2026), $8.9 billion (Q4 2025), and $10.4 billion (Q3 2025), per Business Quant data.